CD274 and diffuse large B-cell lymphoma: Atezoliuzumab, a monoclonal antibody targeting PD-L1, has shown some clinical efficacy in combination with the anti-CD20 obinutuzumab in patients with R/R FL or DLBCL, with preliminary data from a phase-I study showing partial responses in one patient with FL and one with DLBCL out of 5 total evaluable patients (Till et al., 2015).